Novel, potent and highly selective atypical chemokine receptor ACKR3 (CXCR7) agonist. Competes directly with CXCL12-AF647 for ACKR3 binding at low nanomolar concentrations and is more potent in inducing beta-arrestin recruitment to ACKR3 (EC50 = 0.61 nM) than the CXCL12 and CXCL11 chemokine ligands (EC50 = 1.2 and 2.2 nM respectively). Restrains the negative regulatory function of ACKR3 on opioid peptides to potentiate their activity in rat brain.
Purity
>95%
Description
Potent and selective ACKR3 (CXCR7) agonist. Potentiates opioid peptide activity.
Understanding purity and quality - a guide for life scientists
